Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics

• Main Authors: Kit Wun Kathy Cheung (Author), Yang Tang (Author), Doreen Anders (Author), Teresa Barata (Author), Astrid Scalori (Author), Priya Agarwal (Author), Rucha Sane (Author), Sravanthi Cheeti (Author)
• Format: Book
• Published: MDPI AG, 2024-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Pralsetinib is a kinase inhibitor indicated for the treatment of metastatic rearranged during transfection (<i>RET</i>) fusion-positive non-small cell lung cancer. Pralsetinib is primarily eliminated by the liver and hence hepatic impairment (HI) is likely alter its pharmacokinetics (PK)...